Type 2 diabetes - Articles - Page 7

Endocrine/metabolic

Dual and triple agonists of GCG, GIP and GLP-1 receptors disclosed in Sun Pharmaceutical patent

Jan. 7, 2025

Sun Pharmaceutical Industries Ltd. has divulged incretin analogues acting as dual agonists of gastric inhibitory polypeptide (GIPR) receptor/GLP-1 or GLP-1/glucagon receptor (GCGR) or triple agonists of GIPR/GLP-1/GCGR reported to be useful for the treatment of type 2 diabetes, dyslipidemia, obesity, metabolic syndrome, neurodegeneration, fibrosis and cardiovascular disorders.

Diagram of how cells take up glucose from the stomach and insulin from the pancreas

Endocrine/metabolic

Studies of Bio-path’s BP-1001-A show potential in obesity, diabetes

Dec. 20, 2024

Bio-path Holdings Inc. has conducted preclinical studies of BP-1001-A, a drug product modification of prexigebersen, confirming its effectiveness in affecting insulin signaling for the potential treatment of obesity and related metabolic diseases in type 2 diabetes patients.

Freed from clinical hold, Biomea’s menin inhibitor solid in T2D

Dec. 17, 2024

By Lee Landenberger

Released from a clinical hold by the U.S. FDA in late September, Biomea Fusion Inc.’s menin inhibitor, icovamenib, has charged ahead to produce positive top-line data from a phase II study in type 2 diabetes (T2D). The data, however, didn’t stop the stock from dropping to near its lowest level of the past 12 months.

Endocrine/metabolic

Bio-path to develop BP-1001-A to treat obesity in type 2 diabetes patients

Dec. 12, 2024

Bio-path Holdings Inc. has outlined its plans to develop BP-1001-A, a drug product modification of prexigebersen.

Endocrine/metabolic

Discovery of FBPase inhibitor with improved activity and good druggability

Dec. 11, 2024

Work at the Institute of Materia Medica of Beijing has led to the discovery and preclinical characterization of novel fructose-1,6-bisphosphatase (FBPase) inhibitors as potential therapeutic candidates for the treatment of type 2 diabetes.

The DNA double helix overlays a field of ACGTs and binary numbers.

Endocrine/metabolic

Study finds genetic factors behind early-onset type 2 diabetes in South Asians

Dec. 3, 2024

By Nuala Moran

A U.K. study has uncovered distinctive genetic drivers of type 2 diabetes in South Asians that lead to faster development of complications, the need for earlier insulin replacement therapy and a weaker response to some widely prescribed drugs. That points to the need to refine care pathways. But in addition, the research provides a potent illustration of how the under-representation in genomics databases of people who are not of white European origin can skew results and be a source of discrimination.

No plateau: Street level-sets obesity on Amgen Maritide phase II

Nov. 26, 2024

By Randy Osborne

Wall Street began comparing and contrasting what’s available after Amgen Inc. rolled out phase II data with weight loss candidate Maritide – a disclosure that led shares of the biotech heavyweight (NASDAQ:AMGN) to close Nov. 26 at $280.01, down $13.99.

Apollo signs near-$1B deal for Sunshine’s FGF21/GLP-1 injection

Nov. 19, 2024

By Marian (YoonJee) Chu

Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 (FGF21)/glucagon-like peptide-1 (GLP-1) receptor agonist currently in a phase II study for type 2 diabetes.

Apollo signs near-$1B deal for Sunshine’s FGF21/GLP-1 injection

Nov. 13, 2024

By Marian (YoonJee) Chu

Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 (FGF21)/glucagon-like peptide-1 (GLP-1) receptor agonist currently in a phase II study for type 2 diabetes.